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Decamethylcyclopentasiloxane (D5) is a cyclic siloxane used in the production and formulation of con-
sumer products with potential exposure to manufacturing workers, consumer, and the general public.
Following a combined 2-year inhalation chronic bioassay performed in Fischer 344 (F344) rats, an in-
crease in uterine endometrial adenocarcinomas was noted at the highest concentration to which animals
were exposed. No other neoplasms were detected. In this study, a dose of 160 ppm produced an inci-
dence of 8% endometrial adenocarcinomas. Based on a number of experimental studies with D5, the
current manuscript examines the biological relevance and possible modes of action for the uterine
endometrial adenocarcinomas observed in the rat following chronic exposure to D5. Variable rates of
spontaneous uterine endometrial adenocarcinomas have been reported for untreated F344 CrlBr rats. As
such, we concluded that the slight increase in uterine endometrial adenocarcinomas observed in the D5
chronic bioassay might not be the result of D5 exposure but may be related to variability of the spon-
taneous tumor incidence in this strain of rat. However, if the uterine endometrial adenocarcinomas are
related to D5-exposure, alteration in the estrous cycle in the aging F344 rat is the most likely mode of
action. D5 is not genotoxic or estrogenic. The alteration in the estrous cycle is caused by a decrease in
progesterone with an increase in the estrogen:progesterone ratio most likely induced by a decrease in
prolactin concentration. Available data support that exposure to D5 inﬂuences prolactin concentration.
Although the effects on prolactin concentrations in a number of experiments were not always consistent,
the available data support the conclusion that D5 is acting via a dopamine receptor agonist-like
mechanism to alter the pituitary control of the estrous cycle. In further support of this mode of ac-
tion, studies in F344 aged animals showed that the effects of D5 on estrous cyclicity produced a response
consistent with a dopamine-like effect and further suggest that D5 is accelerating the aging of the
reproductive endocrine system in the F344 rat utilized in this study. This mode of action for uterine
endometrial adenocarcinoma tumorigenesis is not relevant for humans.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Background
Decamethylcyclopentasiloxane (D5) is a cyclic siloxane used in
the production of industrial and consumer products with potentialtal Health, Indiana University
IN 47405, USA.
.
Inc. This is an open access article uexposure to consumers, the general public and manufacturing
workers. D5 is used as an intermediate in the production of poly-
dimethylsiloxanes and has a number of secondary uses as a
component in household care and personal care products. D5 is
highly volatile. Based on these properties, consumers, the general
population, and workers may be exposed to D5 by the dermal and
inhalation exposure routes. Dermal absorption of D5 is very limited,
and most of the D5 applied to skin rapidly evaporates (Jovanovic
et al., 2008; Reddy et al., 2007). A number of the toxicity and
pharmacokinetic and metabolism studies with D5 used inhalationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1999; Siddiqui et al., 2007; Tobin et al., 2008; Reddy et al., 2008;
Jean et al., 2015). The available toxicity and mechanistic studies
on D5 are summarized (Dekant and Klaunig, 2015). In a two-year
inhalation chronic bioassay in Fischer 344 (F344) rats (Jean et al.,
2015), a small but statistically signiﬁcant increase in the inci-
dence of uterine endometrial adenocarcinoma in female rats at the
highest dose level of D5 studied (160 ppm) was seen. No other
toxicologically signiﬁcant neoplastic or non-neoplastic ﬁndings
were reported. Given the small increase in the incidence of uterine
endometrial adenocarcinoma seen in the Jean et al. (2015) study at
the highest dose only, a more in-depth evaluation of the statistical
analysis was conducted (Young and Morfeld, 2015) to address the
question of whether the observed uterine endometrial adenocar-
cinoma increase could be spurious. This analysis indicated that
changing the results in one or two animals would impact the
conclusions regarding statistical signiﬁcance. However, the statis-
tical analysis supported the conclusion that D5 at the highest dose
examined resulted in an increased incidence of uterine endometrial
adenocarcinoma in F344 rats.
The purpose of this manuscript is to evaluate the biological
relevance of the uterine endometrial adenocarcinoma in the rat and
to evaluate the potential human relevance of this ﬁnding.
1.2. Carcinogenicity of D5
D5 was tested for carcinogenicity in a two-year chronic
toxicity/carcinogenicity study by inhalation (Jean et al., 2015).
Inhalation exposure was selected because of the rapid loss to
evaporation of D5 applied to the skin, because inhalation is the
second most prevalent exposure route for humans, and because of
the similarity in kinetic behavior between this route and dermal
exposure, the most prevalent route for humans. Male and female
F344 rats were exposed to 0, 10, 40, and 160 ppm D5 (0, 163, 653,
and 2610 mg/m3) for a period of up to two years. A concentration
of 160 ppm D5 in air is the highest vapor concentration of D5 that
can be reliably achieved because aerosols develop at higher vapor
concentrations.
The carcinogenicity study was composed of a primary group of
rats exposed for two years and three additional groups exposed to
D5 for different durations. In the primary group, rats (60 animals
per sex per group) were exposed for 6 h/day and 5 days/week to D5
vapor at 0, 10, 40, and 160 ppm. One group of additional rats (6 per
sex for each of the four D5 concentrations) were exposed to D5
vapor for 6 months and then sacriﬁced with the major aim to
determine D5 concentrations in tissues. A second group of rats,
consisting of 10 animals per sex for each of the four D5 concen-
trations, was sacriﬁced after 12 months of exposure to D5, and a
third group (20 animals/sex for each of the four D5 concentrations)
was also exposed to D5 vapor for 12 months and then observed for
an additional 12 months (recovery) with no exposure before
sacriﬁce.Table 1
Uterine tumor incidence in rats exposed to D5 by inhalation.
Exposure concentration
(ppm D5)
2 year exposure group
Cystic endometrial hyperplasiaa Endometrial adenoc
0 9/60 (15%)b 0/60 (0%)b
10 Not examined 1/60 (2%)
40 Not examined 0/60
160 9/60 (15%) 5/60 (8%)
a Incidence of lesion seen.
b Percent incidence of lesion.No toxicologically relevant effects were seen, except an
increased incidence of hyaline inclusions in the nasal cavity in both
males and females exposed to 160 ppm D5 for six months. Some
statistically signiﬁcant increases in liver weight were also observed,
but these increases were neither D5 concentration- nor exposure-
duration related, suggesting that adaptive responses likely due to
the capacity of D5 to induce liver cytochromes P450 were in effect
(Dekant and Klaunig, 2015).
After 2 years, hyaline inclusions in the nasal cavity were seen in
both male and female rats at 160 ppm in the primary group and in
the 12-month exposure/12-month recovery groups and in males at
40 ppm. The incidences of neoplastic changes in males and females
were not statistically signiﬁcantly different from control, with the
exception of the incidence of uterine tumors. Incidences of uterine
tumor and uterine tumor precursor lesions observed in the onco-
genicity study with D5 by Jean et al. (2015) are shown in Table 1.
An increased incidence of uterine endometrial adenocarcinoma
was seen only in the 160 ppm exposure group after two years of
exposure. However, when comparing the untreated control group
to the 160 ppm exposure treated group, the incidence of uterine
endometrial adenocarcinoma was either signiﬁcantly increased or
of borderline signiﬁcance depending on whether one or two sided
statistical analysis was performed (Young and Morfeld, 2015; Jean
et al., 2015). Neither the incidence of uterine endometrial ade-
noma nor the incidence of uterine endometrial adenomatous
polyps increased; the observed incidence in uterine endometrial
glandular hyperplasia, which is considered to be an obligatory
precursor of uterine adenocarcinoma in rats, was also not increased
at any exposure concentration. No signiﬁcant increases in uterine
endometrial adenocarcinoma or precursor incidences were
observed in the satellite groups (Table 1).
In addition, in rats exposed to D5 vapor for two years, a signif-
icant negative trend for the incidence of ﬁbroadenomas of the
mammary gland (0 ppm, 8/60; 10 ppm, 7/60; 40 ppm, 7/60;
160 ppm, 2/60) was noted.
To understand the possible biological relevance of the uterine
endometrial adenocarcinoma induction following D5 exposure and
the potential impact of the tumor ﬁnding for human risk assess-
ment, a number of factors were considered, including the incidence
of spontaneously occurring uterine endometrial adenocarcinoma in
F344 rats, the uterine tumor types occurring in F344 rats, events
associated with reproductive aging in the female F344 rat, and the
etiology and pathology of adenocarcinoma of the endometrium in
women. These factors are described further below.
2. Overview of rodent uterine endometrial carcinogenesis
The rat uterus is divided into the uterine cervix and corpus. In
rats, tumors of the uterus include both epithelial and non-epithelial
neoplasms. The epithelial neoplasms include adenomas, adeno-
carcinomas, squamous cell papillomas and adenoacanthomas. Non-
epithelial tumors including ﬁbrosarcomas, endometrial stromal1 year exposure/Recovery group
arcinomaa Cystic endometrial hyperplasia Endometrial adenocarcinoma
0/20 (0%) 1/20 (5%)
Not examined 1/20 (5%)
Not examined 0/20 (0%)
2/20 (10%) 2/20 (10%)
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Rat uterine adenomas can be polypoid or sessile while uterine
endometrial adenocarcinomas are frequently polypoid and consist
of irregular glandular structures lined with cuboidal or columnar
cells. The nuclei of the uterine endometrial adenocarcinomas are
usually hyperchromatic and have frequent mitotic ﬁgures. While
these neoplasms occasionally metastasize to distant tissues they
frequently invade the neighboring muscle and adjacent tissue in
the uterus.
In most strains of rats, spontaneous uterine endometrial adeno-
carcinomas are seen with low incidence however Maekawa et al.
(1983) have described a high incidence of uterine endometrial ade-
nocarcinomas in aged Donryu rats. Atypical glandular hyperplasia of
the endometrium is also frequently seen in the rat prior to the
development of uterine adenocarcinomas and may represent a
reversible preneoplastic change (Yoshida et al., 2012). While most
studies assessing the progression of uterine changes preceding
uterine endometrial adenocarcinoma formation have been reported
in the Donryu rat, a similar pathologic progression (from focal
glandular hyperplasia to adenomatous hyperplasia to adenocarci-
noma) appears to also occur in the F344 rat (Tang et al., 1984).
2.1. Overview of the reproductive endocrinology of the aging female
F344 rat
As female F344 rats age, normal estrous cycling ends and the
rats enter a short period of constant estrus (Brown and Leininger,
1992) followed by repetitive pseudopregnancy and anestrus.
Since the D5 chronic bioassay was performed in F344 rats, it is
important to examine the events associated with reproductive
aging in this strain of rat. Constant estrus is characterized by
persistently elevated estrogen levels (Brown and Leininger, 1992;
Lu et al., 1981, 1980b, 1977) and repetitive pseudopregnancy is
characterized by sustained progesterone and prolactin levels. In
anestrus, ovarian activity ceases. Remaining in constant estrus for
any sustained period of time is relatively uncommon for F344 rats
(Nagaoka et al., 1994). Pseudopregnancy occurs at a much higher
incidence in the aging female F344 rat compared to other rat
strains. In the aging female F344 rat, blood prolactin concentrations
increase and dopaminergic inhibition of prolactin secretion via the
tuberoinfundibular dopaminergic (TIDA) neurons decreases. Pro-
lactin normally maintains corpus luteum function and stimulates
the synthesis of progesterone. As a consequence of aging, female
F344 rats enter a state of pseudopregnancy in which elevated
progesterone concentrations are sustained. In pseudopregnancy,
rather than regress, as occurs in young rats that are cycling nor-
mally, the corpora lutea persist and continue to secrete progester-
one. A pseudopregnancy episode usually lasts about 2 weeks,
although longer durations are possible. Animals that become
pseudopregnant usually do so multiple times. As with pregnancy,
pseudopregnancy is associated with high levels of progesterone
and prolactin and low levels of estrogen, luteinizing hormone (LH),
and follicle stimulating hormone (FSH) (Demarest et al., 1982;
Huang et al., 1976; Huang et al., 1978; Lu et al., 1980a; Neumann,
1991; Peluso, 1992; Smith et al., 1975). Pseudopregnancy episodes
and elevation in progesterone occur as early as 12 months of age
(Nagaoka et al., 1994). Consequently, in the aging female F344 rat, a
high level of progesterone relative to estrogen (e.g., a decreased
estrogen/progesterone ratio) from repetitive pseudopregnancy is
the predominant signal to the endometrium.
As female F344 rats enter reproductive senescence and the age-
related changes in the reproductive cycle occur, there are also age-
related changes in the uterus. These include endometrial hyper-
plasia, uterine stromal polyps, and endometrial adenomas
(Leininger and Jokinen, 1990). There are two types of endometrialhyperplasia (Leininger and Jokinen, 1990). The ﬁrst type, diffuse
cystic endometrial hyperplasia, is thought to result from prolonged
estrogen stimulation and is not believed to be preneoplastic. The
second form of hyperplasia, focal glandular hyperplasia (adeno-
matous hyperplasia), however, may be a precursor to the devel-
opment of adenocarcinomas. Uterine stromal polyps, the most
common uterine tumor in rats, form in response to prolonged
progesterone stimulation (Leininger and Jokinen, 1990).
The cause of spontaneous uterine endometrial adenocarcinoma
in rats is unknown, but hormones, in particular a constant estrous
state, and chronic infection have both been suggested to play an
important role (Elsinghorst et al., 1984). Tang et al. (1984) have
examined the effect of changing endocrine status on the uterine
endometrium of the F344 rat in control aging rats, after neonatal
androgenization and after estrogen implant in ovariectomized rats.
These investigators showed that either induced or naturally pre-
sent constant estrous status at 12 months of age led to focal glan-
dular hyperplasia in the F344 rat that did not progress to more
advanced adenomatous hyperplasia until 29 months of age. The
authors suggested that development of a progesterone-insensitive
state associated with the aged endometrium may be required for
the progression to advanced adenomatous hyperplasia and uterine
endometrial adenocarcinoma in the aged F344 rat.
2.2. Incidences of spontaneous uterine tumors in rats
Uterine endometrial adenomas and adenocarcinomas are usu-
ally of relatively low incidence in the F344 rat (Table 2) (Goodman
et al., 1979; Haseman et al., 1998; Maekawa et al., 1983; Solleveld
et al., 1984). Typically, the incidence of endometrial adenocarci-
noma has been reported to be less than 1% at 24 months of age
(Maekawa et al., 1983; Haseman et al., 1998). In F344 rats older than
24months, the incidence of endometrial adenocarcinoma increases
to about 8e12% after 30months (Nyska et al., 1994). In the F344 rat,
the most frequent spontaneous tumor is the endometrial stromal
polyp followed in incidence by the endometrial adenocarcinoma
and endometrial sarcomas. A recent review of the tumor incidence
in control groups from the National Toxicology Program (NTP)
chronic bioassays utilizing the F344 rat has revealed additional
sources of information (Ando et al., 2008; CRL, 1990; Kuroiwa et al.,
2013; Rao et al., 1990; Young and Morfeld, 2015) that challenge the
conclusion of a rare occurrence of these tumors in F344 rats,
particularly in certain sub-strains. The D5 chronic bioassay was
originally compared to NTP historical controls that use the N sub-
strain rather than the historical control data from Charles River,
CrlBR sub-strain, the sub-strain used in the current bioassay.
Nyska and coworkers (Nyska et al., 1994) examined the inci-
dence of spontaneous uterine endometrial adenocarcinoma in F344
rats in their laboratory and compared the uterine endometrial
adenocarcinoma incidence to that reported in the NTP bioassay by
Rao and coworkers (Rao et al., 1990). The F344 inbred rats (F-344
[CrlBR]) in the Nyska laboratory were obtained from Charles River
Laboratories, UK. These rats were used in two studies, an earlier
chronic 2-year study (LSRI-1) and a later chronic bioassay (LSRI-2).
The incidences of uterine endometrial adenocarcinomas in the ﬁrst
study (LSRI-1) (13.3%) were similar to that reported for the NTP
(11%) rats (Rao et al., 1990). However in a later study in the Nyska
Laboratory (LSRI-2) performed approximately 3 years after the
LSRI-1, the incidence of uterine endometrial adenocarcinomaswere
approximately double (24%) compared to the LSRI-1 and the NTP
studies. No difference in adenomas was detected between the two
Nyska studies and the NTP data set. In another study (Kuroiwa et al.,
2013), the incidence of uterine endometrial adenocarcinoma in
F344 rats in chronic bioassays (2-year duration) in the animal fa-
cility was reported for three periods of time. Kuroiwa et al. (2013)
Table 2
Incidences of spontaneous uterine tumors in various rat strains.
Study Strain/Substrain Years studies performed Adenomaa Adeno-carcinomaa Reference
NTP studies F344 N Up to 2012 0.29% 0.29% (NTP, 2013)
NTP (Rao) F344 N 1971e1981 0.2% 11.0% (Rao et al., 1990)
Nyska Study F344 CrlBR 1989e1993 (Nyska et al., 1994)
LSRI-1 0% 13.3%
LSRI-2 0% 24.0%
NTP 0.2% 11.0%
Kuroiwa F344 DuCrlCrlj (Kuroiwa et al., 2013)
1990e1999 ND 3.3%
2000e2004 ND 12.0%
2005e2009 ND 13.5%
Charles River Laboratory F344 CrlBR 1980e1990 ND 8.0% (CRL, 1990)
Haseman F344 N 1971e1997 0.4% 0.7% (Haseman et al., 1998)
Dinse F344 N 1995e2005 0.22% (Dinse et al., 2010)
ND ¼ no data presented.
a Indicates the percentage of tested animals with tumors.
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F344 rats as 3.3% in studies performed from 1990 to 1999, as 12.0%
in rats in studies from 2000 to 2004, and as 13.5% in rats from 2005
to 2009 (Table 2). Data from Charles River (Charles River data, 1990
compilation) demonstrated that the incidence of uterine endome-
trial adenocarcinoma was greater (mean of 8%; 79/950 animals) in
F344/CrlBr used in their facility as compared to the F344/N used by
NTP (0.7% in feeding studies) (Haseman et al., 1998). A more recent
analysis of the NTP database (Dinse et al., 2010) conﬁrmed an
incidence of uterine endometrial adenocarcinoma of 0.22% in F344/
N rats used by NTP.
As noted in Table 2, the incidence of spontaneous uterine
endometrial adenocarcinoma varies with different substrains of
F344 rats and the incidences in sub-strains can change with time.
The higher incidence cited in these additional references was
notably greater than the 0.4e0.7% cited by NTP (Haseman et al.,
1998) that was originally compared to the D5 chronic bioassay
study. The variability the in uterine tumor incidence has important
implications in understanding the relevance of the incidence of
these uterine tumors in the D5 chronic bioassay. Given the rela-
tively low incidence tumors (only in the high dose), the lack of a
dose response in the tumor response and the lack of any tumors
seen in the control group in the D5 chronic bioassay this new in-
formation on the substrain variability of spontaneous uterine tu-
mors in the F344 rat, a re-evaluation of the statistical analysis of the
bioassay was conducted (Young and Morfeld, 2015). For this anal-
ysis, additional historical controls were included in this evaluation
Four sets of control groups speciﬁc to this sub-strain were formed,
with varying heterogeneity. One control group included the con-
current controls for the D5 24-month exposure but also the control
group for the group with 12 months of exposure followed by 12
months of recovery. In addition to the 12-month exposure/12-
month recovery control group in the D5 study, historical control
groups from three additional studies, each of 24-month duration,
were considered: Octamethylcyclotetrasiloxane (D4) (Lee, 2004),
hexamethyldisiloxane (HMDS) (Dotti et al., 2005), and poly-
dimethylsiloxane (PDMS) (Mertens, 2003). Each of the studies had
a 12-month exposure/12-month recovery and a 24-month expo-
sure control group, both of which were considered as potential
historical controls. All studies used the F344 rats of the same strain
and from the same source. The effect of D5 was either statistically
signiﬁcant or showed a borderline signiﬁcance when comparing all
control incidences to the 160 ppm D5 24-month group. Analysis
indicated that changing the results in one or two animals would
impact the conclusions regarding statistical signiﬁcance. The evi-
dence, therefore, supports the conclusion that D5 at the highest
dosage level results in an increased incidence of uterineendometrial adenocarcinomas. However, given the borderline na-
ture of the statistics and the variability of the incidence of this
spontaneous uterine tumor in historical controls in F344 rats, it is
important to assess the biological relevance of this ﬁnding to
further substantiate or counter this effect. It is important to note
that the increased incidence of uterine endometrial adenocarci-
nomas seen with D5 at the highest dose studied cannot be
completely ruled out as being due to variable rates of spontaneous
tumors in the control F344 CrlBr rat substrain.
2.3. Comparison of the histology of the uterine endometrial
adenocarcinoma seen in the D5 study to F344 controls
To better understand the histomorphology of the spontaneous
uterine endometrial adenocarcinoma in aged control F344 rat and
the relationship of these tumors to the uterine endometrial ade-
nocarcinomas found in the D5 two-year bioassay, an independent
pathology review of the uterine tumors was conducted of all F344
female control animals in the NTP historical database that had a
diagnosis of either uterine endometrial adenocarcinoma or uterine
endometrial adenoma and compared to the uterine tumors in the
D5 study (Mann, 2003). The review included NTP control animals
sacriﬁced at 24 months as well as control animals that were
allowed to reach 30 months of age.
The D5-associated uterine endometrial adenocarcinomas were
histologically indistinguishable from uterine endometrial adeno-
carcinomas found in control F344 rats from the NTP studies. There
was a much lower incidence of non-neoplastic changes (cystic
endometrial hyperplasia, epithelial hypertrophy) in the uteri of D5-
exposed F344 rats with uterine endometrial adenocarcinomas that
were present in control F344 rats in the NTP studies. This lack of
preneoplastic changes is inconsistent with typical precursor
changes seen inwomen given unopposed estrogen (Inoue, 2001) or
chemically induced uterine endometrial adenocarcinoma in ro-
dents (Maekawa et al., 1999; Verdeal et al., 1986).
The review of the historical NTP database was based on the
reasoning that the similarity of the morphology of the spontaneous
uterine endometrial adenocarcinomas and uterine endometrial
adenocarcinomas seen in the D5 study might be presumptive evi-
dence that D5was causing an earlier onset of a tumor that increases
spontaneously as the female F344 rat ages and in particular in this
sub-strain of F344 rat. The histological characteristics of the uterine
endometrial adenocarcinomas observed in female rats following
exposure to D5 were indeed indistinguishable from the uterine
endometrial adenocarcinomas present in the control animals in the
NTP studies, providing evidence that D5may simply cause a slightly
earlier onset of a spontaneous tumor in female F344 rats.
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rat
Information on a possible mode-of-action for the induction of
uterine endometrial adenocarcinoma can be derived from a
comparatively large database on chemicals that were tested for
carcinogenicity and induced uterine endometrial adenocarcinoma
in the rat. The agents include genotoxic compounds such as nitro-
samines and aromatic amines (Tanaka and Mori, 1983; Ogino et al.,
1989), hormones and hormonally active chemicals such as 17b-
estradiol (E2) (Yoshida et al., 2012) and tamoxifen (Carthew et al.,
2000), chemicals such as indole-3-carbinol that induce cyto-
chrome P450 1A enzymes resulting in a subsequent modulation of
estrogen metabolism (Yoshida et al., 2012) and dopamine receptor
agonists such as bromocriptine (Alison et al., 1994; Grifﬁth, 1977).
Chemicals with genotoxic properties presumably induce uterine
endometrial adenocarcinoma by an interaction of electrophilic
decomposition products/metabolites with DNA. A direct prolifera-
tive response on the endometrial tissue is the most likely basis for
uterine endometrial adenocarcinoma induction by hormones or
hormonally active chemicals or by chemicals that modulate estro-
gen metabolism favoring formation of estrogen metabolites with
higher potency that strongly activate estrogen receptors. In
contrast, dopamine agonists inhibit prolactin secretion from the
pituitary in rats causing alteration of the estrogen/progesterone
ratio causing estrogen dominance resulting in persistent endome-
trial stimulation ultimately causing endometrial tumors.
In summary, based on the analysis of mechanisms of uterine
endometrial adenocarcinoma in rats, four basic mechanisms can be
derived, including 1) genotoxicity, 2) direct estrogenicity, 3) inter-
ference of administered chemicals with hormone balance such as
p450 1A inducers or active chemicals, and 4) dopamine agonism.
The last three mechanisms all are consequences of a proliferative
stimulus on the endometrium by changes in hormone levels and
include direct hormonal activity and indirect modulation of estro-
gen concentrations by dopamine receptor agonists or agents that
alter estrogen biotransformation.
In the examination of the mechanisms and the biology of uter-
ine endometrial adenocarcinoma formation in the rat, the majority
of the work performed has used the Donryu rat (Yoshida et al.,
2002). The Donryu rat displays a high incidence of spontaneous
endometrial adenocarcinomas that increases with aging. The tu-
mors induced have morphological and biological similarities to
those found in humans. Spontaneous uterine endometrial adeno-
carcinoma development in the Donryu strain has also been linked
to an age-related imbalance of ovarian hormones, speciﬁcally an
increased estrogen:progesterone ratio that occurs much earlier as
compared to the F344 rat. The F344 rat on the other hand repre-
sents a strain that exhibits a slow progression of hyperplasia to
adenocarcinoma (Tang et al., 1984) that is related to age-related
imbalance of ovarian hormones that occurs late in life in the F344
rat leading to an increase in uterine endometrial adenocarcinoma
typically only after 24 months of age.
3. Etiology and pathology of adenocarcinoma of the
endometrium in women
3.1. Occurrence
The most common malignancy of the human uterine corpus is
endometrioid adenocarcinoma of the endometrium. Endometrial
malignancies are mostly adenocarcinomas, although sarcomas
rarely are seen. Among adenocarcinomas, endometrioid histo-
morphology is the predominant subtype. Papillary serous carci-
noma occurs in 3e10% of endometrial adenocarcinomas, and clearcell carcinoma occurs in 0.8e5.5% of endometrial adenocarcinomas,
and both subtypes confer a worse prognosis than does endome-
trioid adenocarcinoma (Cirisano et al., 1999). Undifferentiated tu-
mors and carcinosarcomas are rare and also are associated with a
poor prognosis. Cancer of the uterine corpus increases in the years
prior to menopause and peaks in the ﬁrst decade after menopause.
3.2. The role of estrogen
Most endometrioid endometrial adenocarcinoma is associated
with excessive estrogenic stimulation of the uterine endothelium.
This view was reinforced historically by the observation that
women given estrogen for menopausal therapy demonstrated an
increase in hyperplastic and malignant lesions of the endometrium
(Montgomery et al., 2004).
Among younger women who are diagnosed with endometrioid
endometrial adenocarcinoma, chronic disorders of ovulation are
common (Navaratnarajah et al., 2008). An Australian study of
women younger than 50 with a diagnoses of endometrial adeno-
carcinoma found an increased likelihood that affected women re-
ported a diagnosis of polycystic ovarian syndrome (PCOS) or
symptoms of chronic oligo/anovulation (irregular menses, severe
acne as an adult, hirsuitism), odds ratio 4.3, 95% conﬁdence interval
1.8e10.2 in comparison to a control group without endometrial
adenocarcinoma (Fearnley et al., 2010). A typical feature of PCOS is
irregular or absent ovulation with prolonged exposure of the
endometrium to the proliferative effects of ovarian estrogen
without the counterbalancing effects of luteal progesterone.
Obesity is another risk factor for endometrial adenocarcinoma,
presumably because adipose tissue aromatizes adrenal androgens
to estrogens and produces more frequent or sustained exposure of
the endometrium to estrogenic stimulation. In the Australian study
on PCOS, adjustment for obesity attenuated the increase in risk, and
obesity has been found to be an independent risk factor for endo-
metrial adenocarcinoma (reviewed by Fader et al., 2009). Diabetic
women are also at risk for developing endometrial adenocarcinoma
due to the association of diabetes with obesity and to an inde-
pendent decrease in sex-hormone binding globulin associated with
hyperinsulinemia, which results from insulin resistance. A decrease
in sex-hormone binding globulin results in a higher plasma con-
centration of free (unbound) estrogens.
3.3. Adenocarcinoma of the endometrium not associated with
estrogen in women
Although most endometrioid adenocarcinoma of the endome-
trium is associated with excess estrogen stimulation of the endo-
metrium, some endometrial adenocarcinoma, including serous,
clear cell, undifferentiated, and carcinosarcoma types, arise inde-
pendent of estrogenic stimulation (reviewed by Sherman, 2000). A
distinction between estrogen-dependent “Type 1” adenocarcinoma
and estrogen-independent “Type 2” adenocarcinoma was sug-
gested in 1983. The Type 1 adenocarcinomas arise from a precursor
lesion called atypical hyperplasia, are less aggressive and, in their
earliest stage, may respond to progestin therapy (Randall and
Kurman, 1997). Type 2 tumors, by contrast, do not arise from hy-
perplasia, do not respond to progestin, and arise by mechanisms
not involving unopposed estrogen (Yang et al., 2013). Type 1 lesions
are associated with microsatellite instability and with mutations in
K-RAS, b-catenin, PIK3CA, and PTEN, while Type 2 lesions are asso-
ciated with mutations in P53 and with chromosome abnormalities
(Arafa et al., 2010).
Approximately 1 in 5 women younger than 50 years of age with
endometrial adenocarcinoma have a dominant mutation in a DNA
mismatch repair gene (Walsh et al., 2008). This hereditary
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nonpolyposis colon cancer, and predisposes affected individuals to
cancer of the colon, stomach, ovary, and ureter as well as endo-
metrium. Among womenwith Lynch syndrome, the lifetime risk of
endometrial adenocarcinoma is up to 60% (Aarnio et al., 1999).
Epigenetic silencing of DNA mismatch repair genes may be
responsible for endometrial adenocarcinoma in some women
without the Lynch syndrome; in these cases, microsatellite insta-
bility may be detected in endometrium prior to histological evi-
dence of carcinoma (Faquin et al., 2000). Epigenetic mechanisms in
endometrial adenocarcinoma are discussed further below.
3.4. Mediating factors
3.4.1. CYP 1A1
The naturally occurring estrogens E2 and estrone are oxidized to
catechol estrogens by CYP 1A1 and CYP 1B1. The catechol estrogens
are further oxidized by CYP 1A1 to semiquinones and quinones,
which generate reactive oxygen species through redox cycling. The
reactive metabolites can bind to nucleic acids, producing DNA
damage through adduction (Akanni and Abul-Hajj, 1999).
In humans, it has been proposed that single nucleotide poly-
morphisms (SNPs) of CYP 1A1 that confer increased enzyme ac-
tivity might increase the risk of endometrial adenocarcinoma
through a genotoxic mechanism. In support of this proposal,
caseecontrol studies of women with endometrial hyperplasia and
adenocarcinoma showed that the presence of a valine (for isoleu-
cine) in codon 462 of exon 7 of CYP 1A1 was associated with these
disorders in populations in Spain and Turkey (Esinler et al., 2006;
Esteller et al., 1997). A threonine for asparagine in codon 461 of
CYP 1A1 was also associated with endometrial adenocarcinoma in
Spain (Esteller et al., 1997). However, the isoleucine-to-valine SNP
at codon 462 of exon 7 was not shown to be associated with
endometrial carcinoma in a Japanese population (Sugawara et al.,
2003), and both CYP 1A1 SNPs were associated with a decreased
risk of endometrial carcinoma in a US sample (Doherty et al., 2005).
3.4.2. Glutathione-S-transferase
Glutathione-S-transferases (GSTs) play a role in the detoxiﬁca-
tion of the reactive oxidative metabolites of catechol estrogens. In
humans, SNPs that are associated with a decrease in GSTP1 activity
have been reported to be associated with an increased risk of
endometrial carcinoma (Chan et al., 2005). Other GST poly-
morphisms have not been associated with endometrial cancer risk
(Doherty et al., 2005; Esteller et al., 1997).
3.4.3. Epigenetic changes
In human uterine tumors, hypermethylation of the promoter
region of tumor-suppressor genes is common in type 1 but not type
2 adenocarcinoma of the endometrium (reviewed by Arafa et al.,
2010). Epigenetic inactivation of MLH1, a mismatch repair gene,
and of PTEN are early events in the estrogen-associated hyper-
proliferation leading to adenocarcinoma.
The ﬁnding that tumor-suppressor genes are methylated in
atypical hyperplasia and in histologically normal endometrium
located near foci of endometrioid adenocarcinoma suggests that
epigenetic changes, perhaps estrogen-induced, are early steps in
the carcinogenic process (Arafa et al., 2008).
3.5. Relatedness of human and rat endometrial adenocarcinoma
Female rats appear to develop endometrial adenocarcinoma by
mechanisms similar to those operating in women (Table 3). As
discussed in Section 2.4, above, the most work on spontaneous
adenocarcinoma of the endometrium in rats comes from inbredstrains including Donryu, DA/Han, and BDII/Han, which have high
tumor incidences with age due to mutations in K-ras or tumor
suppressor genes (reviewed by Vollmer, 2003). The uterine ade-
nocarcinomas arising in these animals are morphologically similar
to the endometrioid adenocarcinomas arising inwomen, occur on a
background of endometrial hyperplasia, and are most likely
estrogen-responsive until they become advanced and undifferen-
tiated (Yoshida et al., 2012). The Donryu rat has been shown to have
an increase in estrogen exposure with respect to progesterone
exposure at 12months of age compared to F344 rats, attributable to
disruptions of cycling (Nagaoka et al., 1990). As a consequence,
Donryu rats have a 61% incidence of endometrial hyperproliferative
lesions (endometrial adenocarcinoma, hyperplasia, and adenoma)
with advanced age. This phenomenon is analogous to the increased
exposure to endogenous estrogens in women with disturbances of
ovulation and with obesity.4. Biological relevance for D5 uterine endometrial
adenocarcinoma induction in rats
From the available literature, agents that induce uterine tumors
in rodents appear to function through either DNA interaction by
genotoxic compounds with uterine epithelial cells or through
nongenotoxic effects, speciﬁcally direct activation of estrogen re-
ceptors or modulation of estrogen levels. In the case of the former, a
number of genotoxic carcinogens including nitroso compounds
(ENNG, MNNG, and MNU) have been reported to induce adeno-
carcinomas in the rat uterus Estrogen or compounds that mimic or
modulate estrogen or induce constant estrus have also been shown
to induce uterine endometrial adenocarcinomas in rats. In addition,
oxidative stress and damage derived from estrogen metabolism
and catechol estrogen formation have been proposed (Yoshida
et al., 2012) as possible mechanisms for the induction of uterine
endometrial adenocarcinomas in rats. Modulation of dopamine
levels in the rat have also been linked to uterine cancer formation
due to a modulation of estrogen (Alison et al., 1994).
Based on the available experimental data for D5 coupled with
published studies on the potential mechanisms bywhich chemicals
induce uterine endometrial adenocarcinoma in the rat as well as
proposed mechanisms involved in the process of chemical carci-
nogenesis, we identiﬁed and evaluated several possible modes of
action by which D5 might induce uterine endometrial adenocar-
cinoma in the F344 rat to assess the biological relevance of this
borderline ﬁnding: 1) genotoxicity, 2) direct endocrine (estro-
genicity, androgenicity and progestogenic) activity, 3) oxidative
stress/damage/inﬂammation/cytotoxicity, and 4) alteration of pi-
tuitary control of the estrous cycle. Of these possible modes of ac-
tion, our review of the data from D5 studies supports an alteration
of pituitary control of the estrous cycle as the most probable to be
considered further. Prior to presenting the support for these ﬁnal
conclusions, we will present a summary of the other modes of
action considered and why they are unlikely.4.1. Consideration of other possible modes of action of D5 induced
rat uterine endometrial adenocarcinoma
4.1.1. Genotoxicity as a possible mode of action of D5 induced rat
uterine endometrial adenocarcinoma
Multiple genetic toxicity assessments for D5 have been per-
formed in bacteria, mammalian cells in vitro and in intact animals
in vivo and none have provided evidence that D5 is a genotoxic
chemical (Isquith et al., 1988; Litton, 1978; Dekant and Klaunig,
2015). It was concluded that the genotoxic mode of action does
not apply to D5 induction of uterine tumors in F344 rats.
Table 3
Comparison of endometrial adenocarcinoma in rat and human.
Feature Rat Human Comments
Endometrial hyperplasia
as a precursor lesion
Han-Wistar rat adenocarcinoma starts as nodular
hyperplasia (Deerberg et al., 1981). There are two
types of rodent endometrial hyperplasia. The ﬁrst
type, diffuse cystic endometrial hyperplasia, is
thought to result from prolonged estrogen
stimulation and is not believed to be preneoplastic.
Focal glandular hyperplasia (adenomatous
hyperplasia), however, may be a precursor to
neoplasia (Leininger and Jokinen, 1990)
Endometrial hyperplasia regarded as a precancerous
stage of endometrial adenocarcinoma (reviewed in
Elsinghorst et al., 1984). Human cystic endometrial
hyperplasia is not precancerous, while more complex
hyperplasia with cytologic atypia is premalignant.
Elsinghorst et al. (1984) mentions that it is not known
if the nodular hyperplasia in rats corresponds to any
human hyperplasia subtype
Relationship to parity Virgin Han-Wistar rats used in aging studies
demonstrated 39% incidence of endometrial
adenocarcinoma (reviewed in Deerberg et al., 1981).
Nulliparous women have an increased risk of endometrial
adenocarcinoma (Dossus et al., 2010; Karageorgi
et al., 2010; Pfeiffer et al., 2009).
Schonfeld et al. (2013) report that nulliparity alone does
not modify the risk of endometrial adenocarcinoma over
that associated with hormone-related risk factors, which
may result in subfertility.
Metastasis to lungs in
advanced stage
In Han-Wistar, metastasis to lungs is commonplace
(Deerberg et al., 1981).
Infrequent metastasis to lungs
Types of adenocarcinoma Appears to be estrogen-dependent; not clear that an
estrogen-independent form has been observed in rats.
Type I (estrogen-dependent) and Type II
(estrogen-independent) adenocarcinoma have been
described (Bokhman, 1983)
Role of prolactin Prolactin is luteotropic in rats (Harleman et al., 2012),
maintaining a condition of continuous progesterone
in aged rats, which decreases risk of endometrial
adenocarcinoma.
Prolactin may be a risk factor for endometrial cancers
(Levina et al., 2009). However, prolactin is not luteotropic
in humans (reviewed in Harleman et al., 2012).
Role of obesity Zucker fa/fa obese rats exposed to estrogen
demonstrated signiﬁcantly higher pro-proliferative
genes cyclin A and c-Myc mRNA expression in the
endometrium of obese rats compared to lean control
rats. In addition, anti-proliferative genes RALDH2 and
sFRP4 were not affected by estrogen in obese rats, but
were more strongly induced in lean rats
(Zhang et al., 2009).
Obesity is a major risk factor for endometrial cancer
(reviewed by De Pergola and Silvestris, 2013)
No studies were located that showed more endometrial
adenocarcinoma among obese compared to lean rats.
Relation between
endometrial and
breast cancer
Rats with spontaneous breast cancer may be less prone
to endometrial adenocarcinoma, and vice versa
(Harleman et al., 2012)
Increased exposure to estrogens is a risk factor for
carcinoma at both sites.
PHF5A/PHF5A expression Changes in expression of Phf5a/PHF5A were found in
rat endometrial adenocarcinomas
(Falck and Klinga-Levan, 2013)
Changes in expression of Phf5a/PHF5A were found in
human endometrial adenocarcinomas
(Falck and Klinga-Levan, 2013)
The authors report that the pattern of changes was not
consistent between rats and humans.
Molecular genetic features BDII-Han rats have molecular features closer to
higher-grade human type I tumors with signiﬁcant
down regulation of Pten, Cdh1, p16, Erbb2, and Ctnnb1
(Samuelson et al., 2009)
Type I endometrial adenocarcinoma is characterized
by frequent microsatellite instability and PTEN, K-RAS,
and CTNNB1 mutations; type II adenocarcinoma
displays recurrent TP53 mutation, CDKN2A (P16)
inactivation, over-expression of ERBB2, and reduced
CDH1 expression (Samuelson et al., 2009)
This rat strain is speciﬁcally inbred to produce a model
of human endometrial adenocarcinoma and may not be
generalizable to other rat strains.
Insulin-like growth factor
(IGF) signaling and
susceptibility to
endometrial hyperplasia
IGF-1 signaling is present in rat endometrium after
treatment with estrogen (McCampbell et al., 2008)
Over-expression of IGF-1 is present in complex endometrial
hyperplasia (McCampbell et al., 2008)
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rat uterine endometrial adenocarcinoma
To understand the potential for a direct sustained response of
D5 on endometrial cells, D5 was also assessed for endocrine activity
and was found to not possess any signiﬁcant estrogenic, anti-
estrogenic, progestagenic, androgenic, or anti-androgenic activity
(Quinn et al., 2007b).
Estrogenicity of D5 was assessed in a rat uterotrophic assay in
both SpragueeDawley and F344 rats after D5 inhalation (160 ppm,
whole body, 16 h/day for 3 days). No effects of D5-exposure on the
estrogenic endpoints measured were observed in either strain of
rat. In addition, D5 (10 mM) did not show the capacity to compete
with E2 for binding to the estrogen receptor (ER) in vitro and D5
(10 mM) did not result in a response in an in vitro reporter gene
assay using MCF-7 cells transiently transfected with a plasmid for
ER-a and the luciferase gene. D5 was also negative in a Hershberger
assay assessing potential androgenicity in vivo, and D5 did not
interact with progesterone receptors alpha and beta in vivo.
In a review (Dekant and Klaunig, 2015) to assess a possible role
of membrane and nuclear ER, animals were exposed by inhalation
to D5 (one exposure for 6 or 16 h). Possible D5-mediated effects on
estrogen-dependent endpoints were compared to the response to
ethinyl estradiol and 4-hydroxytamoxifen. Ethinyl estradiol, which
activates both the membrane and nuclear ER, and 4-
hydroxytamoxifen, which activates membrane ER but is a partial
agonist/antagonist for nuclear ER, served as positive controls. Both
positive controls resulted in the expected response, but D5 did not
inﬂuence any of the estrogen-responsive endpoints, including
uterine weight, estrous state, epithelial cell height (luminal and
glandular), histopathology (uterus and mammary gland), and
proliferation (BrdU incorporation) in luminal, glandular, stromal,
and total cells of the uterus and mammary gland. Finally, the his-
topathology from the numerous rat exposure studies with D5 (Jean
et al., 2015; Dekant and Klaunig, 2015) has also failed to support a
direct endocrine effect for the observed uterine tumors. Based on
the results noted above, it is concluded that a direct endocrine
activity mode of action does not apply to D5 induction of uterine
tumors in F344 rats.
4.1.3. Oxidative stress/damage as a possible mode of action of D5-
induced rat uterine endometrial adenocarcinoma
Oxidative stress/damage has been implicated as a cause and/or
promoting component in tumorigenesis (Klaunig, 2004; Klaunig
et al., 2011). In the case of D5, four possible sources of oxidative
damage can be considered in the etiology of uterine tumor induc-
tion. These include the induction of oxidative damage directly from
D5, induction of oxidative damage due to the formation of catechol
estrogens and redox cycling, and oxidative damage from inﬂam-
mation or cytotoxicity. Oxidative stress can result in DNA damage
through formation of oxidative adducts, inhibition of normal DNA
repair, or the production of lipid peroxidation products that form
DNA adducts. Reactive oxygen species can also modify gene
expression, speciﬁcally those genes involved in apoptosis and cell
proliferation.
Oxidative metabolism of estrogens to catechol estrogens has
been suggested as a potential inducer of uterine carcinogenesis.
Estrogens have been shown to undergo oxidative metabolism by
cytochromes P450 1A1 and 1B1 to produce 2-hydroxyestradiol (2-
OHE2) and 4-OHE2. 4-OHE2 has been suspected to have a role in
carcinogenesis as a result of its oxidization to quinone derivatives
(2, 3-OHE2-o-quinone and 3, 4-OHE2-o-quinone). These quinones
have the potential to function at both the initiation and promotion
stage of the cancer process. Ortho-quinones derived from catechol
estrogens are electrophilic DNA reactive compounds. These qui-
nones are also redox cycling agents that are able to generatereactive oxygen species (ROS).
In general toxicology studies changes in liver weight in rats
exposed to high levels of D5 following both oral and inhalation
exposure have been demonstrated. Additional work assessing the
enzyme induction proﬁle in rats treated with D5 demonstrated a
pattern consistent with the classical response observed following
phenobarbital treatment. As is the case for phenobarbital, D5 has
been shown to induce liver enlargement, hepatocellular hypertro-
phy/hyperplasia, and hepatic cytochrome P450 induction (CYP2B1/
2 primarily) in the rat (McKim et al., 1999; Jean et al., 2005). While a
1.8 fold increase in EROD activity was observed, no change in CYP
1A1/2 immunoreactive protein occurred and EROD activity
returned to normal in 14-day post exposure rats.
To assess the impact of D5 on estrogen metabolism, serum was
collected from aging F344 rats exposed to D5 for ~12 months. D5
exposure did not demonstrate a difference in the presence of
estrogen-related analytes (including catechol estrogens) as
compared to controls (Sloter, 2013; Fuhrman et al., 2014). With no
experimental evidence supporting an oxidative or catechol estro-
gen mode of action, it is unlikely this mode of action is responsible
for uterine adenocarcinomas seen following treatment with D5.
Oxidative stress can also be produced subsequent to acute and
chronic inﬂammation. In the case of D5, there is no evidence for an
inﬂammation mode of action in the subchronic and chronic inha-
lation studies with D5. Inﬂammatory changes were not observed in
the uterus in the detailed histopathological examinations of a va-
riety of studies (Jean et al., 2015; Dekant and Klaunig, 2015).
Chronic cytotoxicity with persistent regeneration or compen-
satory hyperplasia of a target tissue has been proposed as a mode of
action for chemical carcinogens. However, there is no evidence
from the subchronic and chronic inhalation studies with D5 for
chronic cytotoxicity in the target tissue based on the histopatho-
logic evaluation of uterine tissues in the oncogenicity study or other
repeated dose studies with D5 (Dekant and Klaunig, 2015).
4.2. Alteration of pituitary control of estrus cycle as a mode of
action of D5-induced rat uterine endometrial adenocarcinoma
4.2.1. Alteration of pituitary control following D5 exposure
This mode of action for the rat uterine tumor induction based on
changes in the estrous cycle associated with D5 exposure is
consistent with some of the experimental data available for D5.
There is evidence that exposure to D5 inﬂuences prolactin con-
centration, although the effects on prolactin are not consistent from
in vivo to in vitro studies (Dekant and Klaunig, 2015). Therefore, the
precise mechanism-of-action for alteration of pituitary control of
the estrus cycle by D5 is not known with certainty. Estrogen
dominance in the rat could occur through a decrease in LH leading
to anovulation and prolonged secretion of endogenous E2 from the
ovary or alteration of prolactin leading to modulation of proges-
terone release from the ovary (Fig. 1).
There are no data showing that D5 treatment alters LH in the rat
in a similar manner as suggested by data for D4. D4 has been shown
to interfere with reproduction in the rat (Meeks et al., 2007)
through suppression of LH (Quinn et al., 2007a). Although D4 and
D5 are structurally similar and have several metabolites in com-
mon, they differ in reproductive endpoints. D4 inhalation was
associated with a decrease in implantations and live litter size
(Quinn et al., 2007a), whereas D5 inhalation had no adverse effects
on reproduction in a two-generation study using the same rat
strain (Siddiqui et al., 2007). In addition, in a two year study with
D4, uterine adenomas with an associated increase in cystic endo-
metrial hyperplasia, which is consistent with elevated endogenous
E2 from ovarian cysts (common with modulations of LH), were
seen. Therefore, the available reproductive data for D5 and
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Fig. 2. Number of times in an estrogenic state (top panel) and number of consecutive
days in an estrogenic state (lower panel). **Statistically different from control at
P < 0.05, 0.01. From Sloter (2013).
Fig. 1. Proposed alteration in estrous cycle mode of action for D5 induce rat uterine
endometrial adenocarcinoma by D5. Alteration of pituitary control of the estrous cycle
in the rat could occur either by alteration in LH or prolactin. The absence of evidence
for D5-associated LH-mediated cycle disruption is represented by the broken line
linking this theoretical mechanism to subsequent events. E/P ¼ estrogen:progesterone.
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D5 do not provide support for D5 alteration of the estrous cycle via
modulation of LH.
Previously studies (Jean, 2005c,b; Jean et al., 2005) suggested
disruption of prolactin/progesterone dominance through dopa-
mine receptor agonism following exposure to D5. More recent
work, including a chronic aged rodent study (Dekant and Klaunig,
2015; Sloter, 2013) supports the conclusion that D5 does not act
directly as a dopamine agonist. However, the following information
is suggestive of dopamine receptor agonist-like and/or partial
agonist/antagonist activity of D5. Mode of action studies show that
D5 decreases pituitary lactotroph release of prolactin in vitro and
modulates circulating prolactin levels in vivo. Further studies
in vitro conﬁrm the effect but suggest it may be an effect on one or
more downstream components of the dopamine signal trans-
duction pathway. Also, repeated D5 exposure via inhalation did not
signiﬁcantly affect circulating prolactin levels after exposure for
one and ﬁve days. However, the average prolactin levels of rats
exposed to D5 for ﬁve days strongly trended higher four and eight
hours post-exposure.
4.2.2. Alteration of estrus cycle following D5 exposure
Data from the aged-animal study show an alteration of the
estrous cycle by D5. To put this observation into perspective, the
regulation of the estrous cycle in the rat needs to be reviewed.
Progesterone from the corpus luteum counters the proliferative
effects of estrogen on the endometrium at least in part by down-
regulating estrogen receptors (reviewed by Oehler et al., 2000).
Endometrial proliferation reﬂects a balance of stimulatory effects of
estrogen and inhibitory effects of progesterone, a relationship that
can be described by the estrogen:progesterone ratio. The typical rat
4-day estrous cycle is characterized by an increase in estrogen on
proestrus followed by the LH surge and ovulation. The corpus
luteum produces a peak in progesterone on estrus, with mainte-
nance of progesterone production through the rest of the cycle and
into the next cycle. Corpus luteum function is maintained by pro-
lactin in the rat, and elevated concentrations of prolactin are
associated with persistence of corpora lutea from previous cycles,
producing a progesterone-dominant pseudopregnancy state.Female rats experience a decreasing number of estrous cycles as
they age and, as discussed above, have prolonged periods of dies-
trus that eventuate in persistent diestrus or pseudopregnancy. The
more estrous cycles in an animal's life, the more proestrus days it
will have experienced and the more estrogen will have stimulated
the endometrium.
Support for alteration of the estrous cycle following exposure to
D5 comes from the study of Sloter, 2013, in which F344 females
were treated with D5 from 11 to 25 months of age with monitoring
of estrous cycle stage by daily vaginal lavage. During the ﬁrst four
months of the exposure period, rats treated with D5 spent more
time in an estrogenic state than did controls and were in an es-
trogenic state for more consecutive days than controls (Fig. 2). In
the D5-exposed rats, the percent of days spent in an estrogenic
state was increased by an average of 44% during the ﬁrst 45-day
interval and 78% during the second 45-day interval. The percent-
age was still increased during the third 45-day interval, even
though the control percentage had increased markedly during this
time. Frequency of estrogenic state was not different from controls
subsequently, as both control and D5-exposed animals converted to
a repeated pseudopregnant state characteristic of the reproduc-
tively senescent F344 rat. A plot (Fig. 3) of the cumulative number
of days in an estrogenic state reveals two inﬂection points, one
when the rats progress from 4- or 5-day cycles to being more
frequently in an estrogenic state (approximately 14 months of age
in controls) and the second when they progress to repetitive
pseudopregnancy (approximately 18 months of age in controls).
Fig. 3. Cumulative days in a high estrogen state associated with D5 and D4 treatment.
From Sloter (2013).
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earlier ages) in the D5-exposed group: 23 days earlier for the ﬁrst
inﬂection point, 16 days earlier for the second. This result suggests
an advancement of aging in the D5-exposed reproductive tracts.
The larger cumulative number of days of estrogen exposure would
be expected to increase the risk of endometrial hyperproliferation.
This study did not show effects on circulating prolactin levels, but
because blood samples were taken only at 3e4-week intervals and
were not normalized to estrous cycle phase, these data cannot
provide much, if any, weight of evidence. Another set of aged F344
rats also were utilized (Dekant and Klaunig, 2015) to evaluate the
effect of an exposure to D5 on cyclicity, prolactin, and estro-
gen:progesterone ratio following exposure at later age. Female
F344 rat aged 22 months were exposed to D5 by inhalation
(160 ppm, 6 h/day, 5 days/week) for three months. The rats were
already in a state of persistent diestrus/pseudopregnancy when the
study began. The effect of D5 was subtle with regard to cyclicity;
however, there was an increase in the days in proestrus/estrus with
the 160 ppm D5 exposure. For the D5 exposed animals, there was
also a subtle effect (albeit using infrequent sampling) on serum
progesterone concentrations, but no real change in prolactin. In
addition, there was an increase in the combined incidence and
severity of focal glandular endometrial hyperplasia (including the
papillary subtype) in the D5 treated animals.
4.2.3. Endometrial hyperproliferation as a precursor lesion
As female rats age, the uterine estrogen and progesterone re-
ceptors show alterations. Uterine trauma in young F344 rats (8e10
months old) produces a decidual cell response comparable to a
pseudopregnant state, but old rats (>20 months old) do not show
this reaction as readily (Saiduddin and Zassenhaus, 1979). Admin-
istration of E2 to ovariectomized rats normally results in an in-
crease in estrogen receptor; administration of progesterone results
in a decrease in estrogen receptor. In aging rats, there is a smaller
increase in estrogen receptor after administration of estrogen and a
smaller decrease in estrogen receptor after administration of pro-
gesterone (Saiduddin and Zassenhaus, 1979). Young and old rats
have the same amount of uterine progesterone receptor, suggesting
that the attenuated response to progesterone in older rats may also
be due to impairment of the function of the receptor or post-
receptor machinery. The decrease in progesterone receptor func-
tion with age would be expected to result in less progesterone
opposition to estrogen-associated endometrial proliferation,
perhaps accounting for the susceptibility of aging F344 rats to
endometrial hyperproliferative lesions (Nyska et al., 1994).The association between estrogen exposure and endometrial
hyperplasia has been demonstrated in aged Fischer rats in vitro and
in vivo (Tang et al., 1982, 1984). The development of hyperplasia is
prevented in the rat by the cyclic appearance of progesterone
associated with pseudopregnancy until 29 months of age where
hyperplasia and adenocarcinoma develop despite the presence of
elevated progesterone, suggesting that the development of more
advanced adenomatous hyperplasia and adenocarcinoma may be
due to a decrease in sensitivity to progesterone. Adenocarcinoma
has been for the most part only rarely observed spontaneously in
control F344 rats before 24 months of age. Focal glandular hyper-
plasia is considered to be a precancerous lesion, in contrast to cystic
hyperplasia, which is not. The distinction between focal glandular
hyperplasia and true neoplasia often is difﬁcult because of the
gradual transition from hyperplasia into adenoma or carcinoma,
which becomes the predominant lesion. Although there was no
reported increase in focal glandular hyperplasia following D5
exposure for 24 months, at least one tumor in the 160 ppm D5
treated group had glandular hyperplasia associated with the tumor
(Jean et al., 2015). Possible explanations for the lack of obvious
associated precursor lesions include focal precursor lesions that
were not detected as a consequence of sampling and sectioning or
onset of low-grade adenocarcinomas months prior to the devel-
opment of persistent diestrus/pseudopregnancy, a state during
which precursor lesions may have regressed. The latter explanation
is supported by the observation (Dekant and Klaunig, 2015) that D5
treatment was associated with an increase in days in estrus shortly
after the initiation of treatment but not thereafter in aged F344 rats
exposed to 160 ppm D5 starting at 11 or 22 months of age. Another
possible explanation is that presence of focal glandular hyperplasia
as a precursor lesion was lost as the tumors progressed to such an
advanced stage that the tumor became the predominant lesion.
This possibility is supported by the shorter term study when aged
F344 rats exposed to D5 staring at 22months showed an increase in
the combined incidence and severity of focal glandular hyperplasia
(including the papillary subtype) in the D5 treated animals. This
ﬁnding suggests that the initial cycle disruption leads to the pre-
cursor lesion (focal glandular hyperplasia) that progress to an
advanced tumor after continued exposure.
4.3. Discussion of proposed mode of action on relevance to humans
As indicated above, reproductive senescence of aging female
F344 rats is characterized by a pseudopregnancy state that is
caused by hypothalamic aging. Hypothalamic aging gives rise to the
loss of dopamine regulation of pituitary prolactin release. As a
consequence, prolactin levels are elevated resulting in persistent
corpora lutea, elevated progesterone and low estrogen. This unique
aspect of reproductive senescence in F344 rats can lead to subtle
changes in these aging animals that are not possible in humans due
to species differences in hormonal regulation. For example, dopa-
mine agonists such as bromocriptine can inhibit prolactin secretion
from the pituitary in rats causing luteolysis and new follicle
development resulting in estrogen dominance (Alison et al., 1994).
This estrogen dominance can lead to endometrial stimulation,
which may lead to endometrial carcinoma. Bromocriptine, a well-
known dopamine agonist, has been reported to produce uterine
endometrial hyperplasia and adenocarcinomas in rats following
chronic administration (NDA 17-962). This carcinogenic effect has
not been demonstrated in any other species including humans
(Burke et al., 1988). In addition, clinical studies with bromocriptine
show no effect on LH, FSH, estrogen levels, progesterone levels, or
endometrial histopathology in women.
In women and other primates, reproductive senescence is very
different from that in rats and occurs relatively late in life (about 51
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(menopause) is the result of ovarian follicular depletion and is not
at all related to aging of the hypothalamus. At the time of meno-
pause, ovarian follicles are essentially depleted and estrogens and
progesterone are severely reduced, but the capacity of the hypo-
thalamus is normal. Also, prolactin decreases after menopause.
Thus, in human females, the post-menopausal period is associated
with elevated LH and FSH secretion and reduced secretion of es-
trogens, progesterone, and prolactin. Based on these differences
and the lack of effects seen in the clinical studies, the tumorigenic
effect of dopamine agonists in female rats should be considered a
species-speciﬁc effect with no risk to human health (Burke et al.,
1988).
Theweight-of-evidence suggests that if even if D5 is responsible
for a slight increase in uterine adenocarcinomas in the rat, this
result is a rat-speciﬁc (and possibly sub-strain-speciﬁc) and has no
relevance to the induction of human uterine adenocarcinomas.
5. Conclusions
Variable rates of spontaneous uterine endometrial adenocarci-
nomas have been reported for untreated F344 CrlBr rats. As such,
we concluded that the slight increase in uterine endometrial ade-
nocarcinomas observed in the D5 chronic bioassaymight not be the
result of D5 exposure but may be related to variability of the
spontaneous tumor incidence in this strain of rat. However, if the
uterine endometrial adenocarcinomas are related to D5-exposure,
a plausible mode of action exists in the rat that involves alteration
in the estrous cycle in the aging F344 rat. The alteration consists of a
decrease in progesterone with an increase in the estro-
gen:progesterone ratio caused most likely by a decrease in pro-
lactin concentration. Suppression of prolactin has been shown in
some but not all studies with D5. It is possible that the in vivo
studies that failed to show suppression of prolactin were not sen-
sitive to alterations that were restricted to a subgroup of suscep-
tible animals or the lack of consistency may be due to the technical
difﬁculty of measuring serum hormones that by their nature are
highly cyclical.
A decrease in progesterone and an increase in the estro-
gen:progesterone ratio is supported by data in 11e25-month-old
rats exposed to D5. The increase in estrogen exposure was docu-
mented during the ﬁrst four months of the exposure period and led
to an increase in the cumulative days of estrogen exposure over the
exposure period when compared to the control animals.
Taken as a whole, the mode of action data of D5 indicates that it
is acting possibly via a dopamine receptor agonist-like mechanism
to alter the pituitary control of the estrous cycle. Like dopamine
receptor agonists, pharmacology studies show that D5 decreases
pituitary lactotroph release of prolactin in vitro and decreases
circulating prolactin levels in vivo in speciﬁc animal models
designed to optimize the release of prolactin, an effect that can be
competed for by a dopamine receptor agonist. Further studies
in vitro conﬁrmed the effect but suggest it may be an effect on one
or more downstream components of the dopamine signal trans-
duction pathway. Studies in aged animals show that the effects of
D5 on estrous cyclicity are consistent with a dopamine-like effect
and further suggest that D5 might be accelerating the aging of the
reproductive endocrine axis in this strain of rat. These results are
consistent with a mode of action for uterine endometrial adeno-
carcinoma tumorigenesis that is not relevant for humans.
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